Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.

Authors :: Phillips, Ryan
Proudfoot, James A.
Davicioni, Elai
Liu, Yang
Spratt, Daniel Eidelberg
Feng, Felix Y
Simko, Jeff
Den, Robert Benjamin
Pollack, Alan
Rosenthal, Seth A.
Sartor, A. Oliver
Sweeney, Christopher
Attard, Gerhardt
Patel, Samir
Straza, Michael Wayne
Efstathiou, Jason A.
Shah, Amit
Rodgers, Joseph P.
Sandler, Howard M.
Tran, Phuoc T.
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p5094-5094, 1p
Publication Year :: 2023

Full Text Access

Tools